Analystreport

Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its price target lowered by analysts at Mizuho to $34.00.

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com